Handbook of Cannabis Pertwee, Roger (ed.)
Oxford University Press. 2014.

Activation of CB2 receptors as a potential therapeutic target for migraine: evaluation in an animal model. Greco, Rosaria, et al.
The Journal of Headache and Pain. 2014, 15:14.

Activation of cannabinoid receptor 2 attenuates synovitis and joint destruction in collagen-induced arthritis. Gui, H, et al.
Immunobiology. 2014 Dec.30 (abstract).

Medical marijuana laws and suicides by gender and age. Anderson, DM, et al.
American Journal of Public Health. 2014 Dec. 104(12): 2369-2376 (abstract).

Elevated CB1 and GPR55 receptor expression in proximal tubule cells and whole kidney exposed to diabetic conditions. Jenkin, KA, et al.
Clinical and Experimental Pharmacology & Physiology. 2014 Dec.29 (abstract).

Neural effects of cannabinoid CB1 neutral antagonist tetrahydrocannabivarin (THCv) on food reward and aversion in healthy volunteers. Tudge, L, et al.
International Journal of Neuropsychopharmacology. 2014 Dec.25.

Involvement of central and peripheral receptors on antinociceptive effect of tetrahydrocannabinol in muscle pain. Bagüés, A et al.
European Journal of Pharmacology. 2014 Dec.15, 745:69-75 (abstract).

Chronic Stimulation of the tone of endogenous anandamide reduces cue-and stress-induced relapse in rats. Chauvet, C, et al.
International Journal of Neuropsychopharmacology. 2014 Dec.5.

Experience of adjunctive cannabis use for chronic non-cancer pain: findings from the pain and opioids in treatment (POINT) study. Degenhardt, L et al.
Drug Alcohol Dependence. 2014 Dec.10 (abstract).

Effects of marijuana exposure on expiratory airflow: a study of adults who participated in the U.S. national health and nutrition examination study. Kempker, JA, et al.
Annals of the American Thoracic Society. 2014 Dec.18 (abstract).

Protective effects of cannabidiol on lesion-induced intervertebral disc degeneration. Silveira, JW, et al.
PLoS One. 2014 Dec.17 9(12).

The combination of cannabidiol and ∆9-tetrahydrocannabinol enhances the anticancer effects of radiation in an orthotopic murine glioma model. Scott, Katherine A, et al.
Molecular Cancer Therapeutics. 2014 Dec.13 (12): 2955-67 (abstract).

Inhibition of monoacylglycerol lipase prevents chronic traumatic encephalopathy-like neuropathology in a mouse model of repetitive mild closed head injury. Zhang, J, et al.
Journal of Cerebral Blood Flow & Metabolism. 2014 Dec. 10 (abstract).

Distinct interactions of cannabidiol and morphine in three nociceptive behavioral models in mice. Neelakantan, H, et al.
Behavioral Pharmacology. 2014 Dec.5 (abstract).

Gross morphological brain changes with chronic, heavy cannabis use. Lorenzetti, V, et al.
British Journal of Psychiatry. 2014 Nov. 27 (abstract).

∆9 Tetrahydrocannabinol attenuates staphylococcal enterotoxin B-induced inflammatory lung injury and prevents mortality in mice by modulation of miR-17-92 cluster and induction of T-regulatory cells. Rao, R, et al.
British Journal of Pharmacology. 2014 Nov. 26 (abstract).

Anti-aversive role of the endocannabinoid system in the periaqueductal gray stimulation model of panic attacks in rats. Viana, TG, et al.
Psychopharmacology(Berl.). 2014 Nov.13 (abstract).

High-intensity cannabis use associated with lower plasma human immunodeficiency virus-1 RNA viral load recently infected people who use injection drugs. Milloy, MJ, et al.
Drug Alcohol Review. 2014 Nov. 11 (abstract).

Cannabinoid CB2 receptors modulate midbrain dopamine neuronal activity and dopamine-related behavior in mice. Zhang, Hai-Ying et al.
Proceedings of the National Academy of Sciences. 2014 Nov.3 E5007-E5015.

Effect of marijuana use on outcomes in traumatic brain injury. Nguyen, B M, et al.
American Journal of Surgery. 2014 Oct. 80(10): 979-83 (abstract).

Legalization of medical marijuana and incidence of opioid mortality. Hayes, Marie J, et al.
JAMA Internal Medicine. 2014, 174(10): 1673-1674 (abstract).

Colon carcinogenesis is inhibited by the TRPM8 antagonist cannabigerol, a cannabis-derived non-psychotropic cannabinoid. Borrelli, F, et al.
Carcinogenesis. 2014 Sep.30 (abstract).

Cannabinoid type 1 receptor availability in the amygdala mediates threat processing in trauma survivors. Pietrzak, Robert H, et al.
Neuropsychopharmacoloy. 2014, 39:2519-2528 (abstract).

The fatty acid amide hydrolase inhibitor PF-3845 promotes neuronal survival attenuates inflammation and improves functional recovery in mice with traumatic brain injury. Tchantchou, F, et al.
Neuropharmacology. 2014, Oct. 85: 427-39 (abstract).

Couples’ marijuana use is inversely related to their intimate partner violence over the first 9 years of marriage. Smith, P H, et al.
Psychology of Addictive Behaviors. 2014 Sep, 28(3): 734-742 (abstract).

Cannabidiol improves vasorelaxation in Zucker Diabetic fatty rats through cyclooxygenase activation. Wheal, A J, et al.
Journal of Pharmacology and Experimental Therapeutics. 2014 Sep 11 (abstract).

Drug-resistant MS spasticity treatment with Sativex® add-on and driving ability. Freidel, M, et al.
Acta Neurologica Scandinavica. 2014 Sep 11.

Medical cannabis laws and opioid analgesic overdose mortality in the United States, 1999-2010. Bachhuber, M A, et al.
JAMA Internal Medicine. 2014 Aug 25 (abstract).

Preliminary, open-label, pilot study of add-on oral ∆9-tetrahydrocannabinol in chronic post-traumatic stress disorder. Roitman, P, et al.
Clinical Drug Investigation. 2014 Aug, 34(8): 587-591 (abstract).

β-Caryophyllene ameliorates the Alzheimer-like phenotype in APP/PS1 mice through CB2 receptor activation and the PPARy pathway. Cheng, Y, et al.
Pharmacology. 2014 Aug, 94(1-2): 1-12 (abstract).

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Sexton, M, et al.
Inflammopharmacology. 2014 Oct, 22(5): 295-303 (abstract).

Cannabis-based medicine reduces multiple pathological processes in AβPP/PS1 mice. Aso, E, et al.
Journal of Alzheimers Disease. 2014, Aug 14 (abstract).

Cannabionoids increase lung cancer cell lysis by lymphokine-activated killer cells via upregulation of ICAM-1. Haustein, M, et al.
Biochemical Pharmacology. 2014 Jul 25, 15:92 (abstract).

The association between cannabis abuse and subsequent schizophrenia: a Swedish national co-relative control study. Giordano, G N, et al.
Psychological Medicine. 2014 Jul 3: 1-8 (abstract).

Use of a synthetic cannabinoid in a correctional population for post-traumatic stress disorder-related insomnia and nightmares, chronic pain, harm reduction, and other indications: a retrospective evaluation. Cameron, C, et al.
Journal of Clinical Psychopharmacology. 2014 Oct, 34(5): 559-564.

The impact of cannabis use on clinical outcomes in recent onset psychosis. Barrowclough, C, et al.
Schizophrenia Bulletin. 2014 July 9 (abstract).

Does the legalization of medical marijuana increase completed suicide? Rylander, M, et al.
The American Journal of Drug and Alcohol Abuse. 2014 Jul, 40(4): 269-273.

Type-1 cannabinoid receptor activity during Alzheimer’s disease progression. Manuel, I, et al.
Journal of Alzheimers Disease. 2014 Jun 19, 42(3): 761-766 (abstract).

Patterns of use of medical cannabis among Israeli cancer patients: a single institution experience. Waissengrin, B, et al.
Journal of Pain Symptom Management. 2014 Jun 14, pii: S0885-3924(14)00312-1 (abstract).

Long-term effectiveness and safety of nabiximols (tetrahydrocannabinol/cannabidiol oromucosal spray) in clinical practice. Flachenecker, P, et al.
European Neurology. 2014 Jun 18, 72(1-2): 95-102 (abstract).

Cannabis smoking and lung cancer risk: pooled analysis in the international lung cancer consortium. Zhang, L R, et al.
International Journal of Cancer. 2014 Jun 30.

Genetic predisposition to schizophrenia associated with increased use of cannabis. Power, R A, et al.
Molecular Psychiatry. 2014 Jun 24, EISSN: 1476-5578 (abstract).

β-Caryophyllene, a CB2 receptor agonist produces multiple behavioral changes relevant to anxiety and depression in mice. Bahi, A, et al.
Physiology & Behavior. 2014 Jun 13, 135C: 119-124 (abstract).

Cannabidiol can improve complex sleep-related behaviours associated with rapid eye movement sleep behaviour disorder in Parkinson’s disease patients: a case series. Chagas, M H, et al.
Journal of Clinical Pharmacy and Therapeutics. 2014 May 21, 2014 Oct, 39(5): 564-566 (abstract).

Cannabis and cannabinoids (PDQ). health professional version. National Cancer Institute. May 13 2014.

Δ9-Tetrahydrocannabinol prevents methamphetamine-induced neurotoxicity. Castelli, Paola M, et al.
PLoS One. 2014: 9(5): e98079.

Impact of substance use on conversion to psychosis in youth at clinical high risk of psychosis. Buchy, L, et al.
Schizophrenia Research. 2014 May, 156(2-3): 277-280 (abstract).

Fasting and exercise increase plasma cannabinoid levels in THC pretreated rats: an examination of behavioural consequences. Wong, A, et al.
Psychopharmacology. 2014 Apr 3 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of parkinson disease: an open-label observational study. Lotan, I, et al.
Clinical Neuropharmacology. 2014 Mar-Apr, 37(2): 41-44 (abstract).

Endocannabinoid-hydrolysing enzymes in the post-mortem cerebellum of humans affected by hereditary autosomal dominant ataxias. Rodriguez-Cueto, C, et al.
Pathobiology. 2014 Mar 14, 81(3): 49-159 (abstract).

Anandamide inhibits breast tumor-induced angiogenesis. Picardi, P, et al.
Translational Medicine. 2014, 10(3): 8-12.

Subtypes of attention deficit-hyperactivity disorder (ADHD) and cannabis use. Loflin, Mallory, et al.
Substance Use & Misuse. 2014 Mar, 49(4): 427-434 (abstract).

Neuroprotective effects of the cannabinoid agonist HU210 on retinal degeneration. Lax, Pedro, et al.
Experimental Eye Research. 2014 Mar, 120: 175-185 (abstract).

Chronic cannabidiol treatment improves social and object recognition in double transgenic APPswe/PS1Δ E9 Mice. Cheng, D, et al.
Psychopharmacology. 2014 Aug, 231(15): 3009-3017 (abstract).

That which we call Indica, by any other name would smell as sweet. Erkelens, Jacob L, et al.
Cannabinoids. 2014, 9(1): 9-15.

Nabiximols (THC/CBD oromucosal spray, sativex in clinical practice-results of a multicenter, non-interventional study (move2) in patients with multiple sclerosis spasticity. Flachenecker, P, et al.
European Neurology. 201, 71(5-6): 271-279 (abstract).

Effects of WIN 55,212-2 (a non-selective cannabinoid CB1 and CB2 receptor agonist) on the protective action of various classical antiepileptic drugs in the mouse 6 Hz psychomotor seizure model. Florek-Luszczki, Magdalena, et al.
Journal of Neural Transmission. 2014 Feb 19, 121(7): 707-715.

Protective effects of cannabidiol against hippocampal cell death and cognitive impairment induced by bilateral common carotid artery occlusion in mice. Schiavon, A P, et al.
Neurotoxicity Research. 2014 Feb 15 (abstract).

Experimental colitis in mice is attenuated by changes in the levels of endocannabinoid metabolites induced by selective inhibition of fatty acid amide hydrolase (FAAH). Salaga, M, et al.
Journal of Chronic Colitis. 2014 Sep 1, 8(9): 998-1009.

Evaluation of selective of cannabinoid CB(1) and CB(2) receptor agonists in a mouse model of lipopolysaccharide-induced interstitial cystitis. Tambaro, S, et al.
European Journal of Pharmacology. 2014 Apr 15, 729: 67-74 (abstract).

Cannabinoids inhibit cholinergic contraction in human airways through prejunctional CB1 receptors. Grassin-Delyle, S, et al.
British Journal of Pharmacology. 2014 Jun, 171(11): 2767-2777 (abstract).

Emerging clinical applications for cannabis and cannabinoids. A review of the recent scientific literature. Sixth
Edition.
Armentano, Paul.
The National Organization for the Reform of Marijuana Laws. Jan 13 2014: 1-69 (see separate binder).

Cannabidiol as a potential treatment for psychosis. Schubart, C D, et al.
European Neuropsychopharmacology. 2014 Jan, 24(1): 51-64 (abstract).

Cannabis (medical marijuana) treatment for motor and non-motor symptoms of Parkinson’s disease: an open-label observational study. Lotan, I, et al.
Clinical Neuropharmacology. 2014 Mar, 37(2): 41-44 (abstract).

Care and feeding of the endocannabinoid system: A systematic review of potential interventions that upregulate the endocannabinoid system. McPartland, John M, et al.
PLOS One. 2014 Mar, 9(3): 1-21.

The cannabinoid CB2 receptor-selective phytocannabinoid beta-caryophyllene exerts analgesic effects in mouse models of inflammatory and neuropathic pain. Klauke, A L, et al.
European Neuropsychopharmacology. 2014 Apr, 24(4): 608-620 (abstract).

Interleukin 17A evoked mucosal damage is attenuated by cannabidiol and anandamide in a human colonic explant model. Harvey, B S, et al.
Cytokine. 2014 Feb, 65(2): 236-244 (abstract).

A controlled family study of cannabis users with and without psychosis. Proal, A C, et al.
Schizophrenia Research. 2014 Jan, 152(1): 283-288 (abstract).

Clinical endocannabinoid deficiency (CECD) revisited: can this concept explain the therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Smith, S C, et al.
Neuro Endocrinology Letters. 2014 35(3): 198-201 (abstract).

Early phytocannabinoid chemistry to endocannabinoids and beyond. Mechoulam, Raphael et al.
Nature Reviews/Neuroscience 2014 Nov. 15: 757-764.

ENTER YOUR EMAIL AND GET

10% OFF

YOUR NEXT ORDER

Be the first to learn about our new product additions, events and special promotions.